Eye - subfoveal choroidal neovascularisation
The PBS subsidises aflibercept and ranibizumab for patients with subfoveal choroidal neovascularisation (CNV).
The PBS subsidises treatment with aflibercept and ranibizumab under the National Health Act 1953, Section 85 for patients with subfoveal CNV.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing aflibercept and ranibizumab.
To be eligible for PBS subsidised treatment with these medications, patients must be treated by:
- an ophthalmologist
- an accredited ophthalmology registrar in consultation with an ophthalmologist.
Applying for initial treatment
Apply for authority approval to prescribe initial PBS subsidised aflibercept and ranibizumab in writing and either:
All applications must include the completed:
- authority prescription form or forms
- Subfoveal choroidal neovascularisation Initial PBS authority application form (PB072)
- relevant attachments.
Applications to move between different drugs to treat CNV will require a new initial authority application to be completed.
Applying for continuing treatment
Applications for continuing authority applications to prescribe PBS subsidised aflibercept and ranibizumab can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for further information.
Page last updated: 1 October 2020
This information was printed 11 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/eye-subfoveal-choroidal-neovascularisation. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.